FTC Chief Says Generic-Drug Deals Cost Public $3.5B
Although the Hatch-Waxman Act worked for a time, it has been derailed by anti-competitive settlements — known as “pay-for-delay settlements” or “reverse payments” — between the two types of manufacturers, he said in a speech to the Center for American Progress.
Generics, with their cheaper prices and lower profit margins,...
Already a subscriber? Click here to login